Show simple item record

dc.contributor.authorCueto, F. J.
dc.contributor.authorDel Fresno, C.
dc.contributor.authorBrandi, P.
dc.contributor.authorCombes, A. J.
dc.contributor.authorHernández-García, E.
dc.contributor.authorSánchez-Paulete, A. R.
dc.contributor.authorEnamorado, M.
dc.contributor.authorBromley, Christian P
dc.contributor.authorGomez, M. J.
dc.contributor.authorConde-Garrosa, R.
dc.contributor.authorMañes, S.
dc.contributor.authorZelenay, Santiago
dc.contributor.authorMelero, I.
dc.contributor.authorIborra, S.
dc.contributor.authorKrummel, M
dc.contributor.authorF.Sancho, D.
dc.date.accessioned2021-07-19T10:28:52Z
dc.date.available2021-07-19T10:28:52Z
dc.date.issued2021en
dc.identifier.citationCueto FJ, del Fresno C, Brandi P, Combes AJ, Hernández-García E, Sánchez-Paulete AR, et al. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J Immunother Cancer. 2021 May;9(5):e002054. en
dc.identifier.pmid33980589en
dc.identifier.doi10.1136/jitc-2020-002054en
dc.identifier.urihttp://hdl.handle.net/10541/624124
dc.description.abstractBackground: Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet. Methods: B16 and MC38 tumor cell lines were inoculated subcutaneously into wild-type (WT) and DNGR-1-deficient mice. To overexpress Flt3L systemically, we performed gene therapy through the hydrodynamic injection of an Flt3L-encoding plasmid. To characterize the immune response, we performed flow cytometry and RNA-Seq of tumor-infiltrating cDC1s. Results: Here, we found that cross-presentation of tumor antigens in the steady state was DNGR-1-independent. However, on Flt3L systemic overexpression, tumor growth was delayed in DNGR-1-deficient mice compared with WT mice. Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. Mechanistically, the deficiency in DNGR-1 boosted an Flt3L-induced specific inflammatory gene signature in cDC1s, including Ccl5 expression. Indeed, the increased infiltration of cDC1s within tumors and their protective effect rely on CCL5/CCR5 chemoattraction. Moreover, FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer. Notably, cyclophosphamide elevated serum Flt3L levels and, in combination with the absence of DNGR-1, synergized against tumor growth. Conclusion: DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/jitc-2020-002054en
dc.titleDNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cellsen
dc.typeArticleen
dc.contributor.departmentCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.en
dc.identifier.journalJournal for Immunotherapy of Canceren
dc.description.noteen]
refterms.dateFOA2021-07-26T10:15:45Z


Files in this item

Thumbnail
Name:
33980589.pdf
Size:
2.701Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record